Subgroup Analyses of EMPOWER-LUNG 1

Ibtrozi had a 90% response rate in treatment naïve adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer, according to the results of a news release.

Findings mark the first time a neoadjuvant immunotherapy regimen has demonstrated a significant survival benefit in a randomized phase 3 trial of a solid tumor.

Tracking the trajectory of symptoms may be an improvement over the traditional way of collecting patient-reported outcomes

A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain metastases, and improved quality of life in patients with advanced ALK-positive lung cancer.

Immune checkpoint inhibitors, such as Opdivo (nivolumab) and Keytruda (pembrolizumab), have been a huge advance in the treatment of non-small cell lung cancer. But it is open question whether they should be combined with traditional chemotherapy.